An analysis of the Study Of diabetic Nephropathy with AtRasentan trial also found that both body weight and BNP were independently associated with hospitalization for heart failure during treatment with the ERA atrasentan in patients with type 2 diabetes and CKD.14 Independent statistically significant associations in multivariable regression suggest that these markers may reflect distinct aspects of fluid retention. The gene discussed is NPPB; the disease is chronic kidney disease.